Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis

References

• Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570–2581.
   PubMed Web of Science ®Google Scholar
• Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.
   PubMed Web of Science ®Google Scholar
• Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141–149.
   PubMed Web of Science ®Google Scholar
• De Meel RHP, Tannemaat MR, Verschuuren J. Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord. 2019;29:664–670.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.
   PubMed Web of Science ®Google Scholar
• Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60:707–715.
   PubMed Web of Science ®Google Scholar
• Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7:e013278.
   PubMed Web of Science ®Google Scholar
• Twork S, Wiesmeth S, Klewer J, et al. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.
   PubMed Web of Science ®Google Scholar
• Kulkantrakorn K, Sawanyawisuth K, Tiamkao S. Factors correlating quality of life in patients with myasthenia gravis. Neurol Sci. 2010;31:571–573.
   PubMed Web of Science ®Google Scholar
• Blum S, Lee D, Gillis D, et al. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22:1164–1169.
   PubMed Web of Science ®Google Scholar
• Xin H, Harris LA, Aban IB, et al. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America Patient Registry sample. J Clin Neurol. 2019;15:376–385.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–1036.
   PubMed Web of Science ®Google Scholar
• Ramizuddin K, Ramizuddin MK. Review on: mayasthenia gravis and telithromycin-myasthenia crisis. IOSR J Dent Med Sci. 2014;13:67–97.
   Google Scholar
• Filosso PL, Galassi C, Ruffini E, et al. Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study. Eur J Cardiothorac Surg. 2013;44:219–224.
   PubMed Web of Science ®Google Scholar
• Nacu A, Andersen JB, Lisnic V, et al. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity. 2015;48:362–368.
   PubMed Web of Science ®Google Scholar
• Chang K-H, Lyu R-K, Ro L-S, et al. Coexistence of pernicious anemia and myasthenia gravis—a rare combination of autoimmune diseases in Taiwan. J Formos Med Assoc. 2006;105:946–949.
   PubMed Web of Science ®Google Scholar
• Farmakidis C, Pasnoor M, Dimachkie MM, et al. Treatment of myasthenia gravis. Neurol Clin. 2018;36:311–337.
   PubMed Web of Science ®Google Scholar
• Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012;78:1601–1607.
   PubMed Web of Science ®Google Scholar
• Fang F, Sveinsson O, Thormar G, et al. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med. 2015;277:594–604.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054–1059.
   PubMed Web of Science ®Google Scholar
• Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985;48:1246–1252.
   PubMed Web of Science ®Google Scholar
• Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304–2311.
   PubMed Web of Science ®Google Scholar
• Messéant J, Dobbertin A, Girard E, et al. MuSK frizzled-like domain is critical for mammalian neuromuscular junction formation and maintenance. J Neurosci. 2015;35:4926–4941.
   PubMed Web of Science ®Google Scholar
• Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69:445–451.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Skeie GO, Romi F, et al. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12:259–268.
   PubMed Web of Science ®Google Scholar
• Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology. 1993;43:1167–1172.
   PubMed Web of Science ®Google Scholar
• Engel AG, Lindstrom JM, Lambert EH, et al. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology. 1977;27:307–315.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412:113–128.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Vanoli F, Frangiamore R, et al. Complement inhibition for the treatment of myasthenia gravis. Immunotargets Ther. 2020;9:317–331.
   PubMed Web of Science ®Google Scholar
• Kordas G, Lagoumintzis G, Sideris S, et al. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS One. 2014;9:e108327.
   PubMed Web of Science ®Google Scholar
• Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116:2843–2854.
   PubMed Web of Science ®Google Scholar
• Tuzun E, Huda R, Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun. 2011;37:136–143.
   PubMed Web of Science ®Google Scholar
• Kusner LL, Kaminski HJ, Soltys J. Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol. 2008;4:43–52.
   PubMed Web of Science ®Google Scholar
• Kusner LL, Kaminski HJ. The role of complement in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci. 2012;1274:127–132.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Arouche-Delaperche L, Preusse C, et al. Necrosis in anti-SRP(+) and anti-HMGCR(+) myopathies: role of autoantibodies and complement. Neurology. 2018;90:e507–e517.
   PubMed Web of Science ®Google Scholar
• Wiedmer T, Hall SE, Ortel TL, et al. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192–1196.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450–1461.
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–1687.
   PubMed Web of Science ®Google Scholar
• Kjaeldgaard AL, Pilely K, Olsen KS, et al. Amyotrophic lateral sclerosis: the complement and inflammatory hypothesis. Mol Immunol. 2018;102:14–25.
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893–902.
   PubMed Web of Science ®Google Scholar
• Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175:408–418.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511–522.
   PubMed Web of Science ®Google Scholar
• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419–425.
   PubMed Web of Science ®Google Scholar
• Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.
   PubMed Web of Science ®Google Scholar
• Bansal R, Goyal MK, Modi M. Management of myasthenia gravis during pregnancy. Indian J Pharmacol. 2018;50:302–308.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Adcock L. CADTH rapid response reports. Rituximab for the treatment of myasthenia gravis: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018.
   Google Scholar
• Nowak RJ. B cell targeted treatment in myasthenia gravis (BeatMG)-a phase 2 trial of rituximab in myasthenia gravis: topline results. Neurology. 2018;90:e2182–e2194.
   Google Scholar
• Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020;77:974–981.
   PubMed Web of Science ®Google Scholar
• Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis: extended prospective study results. Muscle Nerve. 2018;58:452–455.
   PubMed Web of Science ®Google Scholar
• Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89:1069–1077.
   PubMed Web of Science ®Google Scholar
• Sinclair A, Nicolau I, Xie X, et al. The effectiveness and safety of rituximab (anti-CD20) in neurologic autoimmune diseases. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC). 2013. [cited 2020 May 20]. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2013_64_rituximab.pdf
   Google Scholar
• Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48:76–84.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Soliris (eculizumab): summary of product characteristics. Levallois-Perret, France: Alexion Europe SAS; 2020.
   Google Scholar
• Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976–986.
   PubMed Web of Science ®Google Scholar
• FDA approves Soliris (eculizumab) for the treatment of patients with generalized myasthenia gravis (gMG) [Internet]. 2017. [cited 2020 May 20]. Available from: https://ir.alexion.com/news-releases/news-release-details/fda-approves-solirisr-eculizumab-treatment-patients-generalized
   Google Scholar
• Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78:367–376.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Soliris (eculizumab): US prescribing information. Boston, MA: Alexion Pharmaceuticals, Inc.; 2019.
   Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632–639.
   PubMed Web of Science ®Google Scholar
• Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol. 2015;6:21–31.
   Google Scholar
• Zelek WM, Xie L, Morgan BP, et al. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341–352.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16:601–617.
   PubMed Web of Science ®Google Scholar
• New HR. Approaches to targeting B cells for myasthenia gravis therapy [review]. Front Immunol. 2020;11:240.
   Web of Science ®Google Scholar
• Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86:255–260.
   PubMedGoogle Scholar
• Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis – results from population based cohorts. Health Qual Life Outcomes. 2015;13:115.
   PubMedGoogle Scholar
• Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77:582–592.
   PubMed Web of Science ®Google Scholar
• Johnston J, Ricardo A, Arata M, et al. A phase 1 multiple-dose clinical study of RA101495, a subcutaneously administered synthetic macrolytic peptide inhibitor of complement C5 for treatment of paroxysmal noctural hemogloginuria [abstract LB2249]. Haematologica. 2016;101:415–416.
   Google Scholar
• Johnston J, Ricardo A, Arata M, et al. A phase 1 single-ascending-dose clinical study of RA101495, a subcutaneously administered synthetic macrocyclic peptide inhibitor of complement C5 for treatment of paroxysmal nocturnal hemoglobinuria [abstract P632]. Haematologica. 2016;101:247–248.
   Web of Science ®Google Scholar
• Inglis JE, Radziwon KA, Maniero GD. The serum complement system: a simplified laboratory exercise to measure the activity of an important component of the immune system. Adv Physiol Educ. 2008;32:317–321.
   PubMed Web of Science ®Google Scholar
• Ricardo A, Duda PW, Farzaneh-Far R, et al. Mechanistic and pharmacological differentiation of zilucoplan, a macrocyclic peptide inhibitor of complement component 5 (C5), from anti-C5 monoclonal antibodies. Presented at American Association of Neuromuscular & Electrodiagnostic Medicine, October 16–19, 2019; Austin, TX.
   Google Scholar
• Myasthenia Gravis Foundation of America. Myasthenia gravis: a manual for the health care provider. New York, NY: Myasthenia Gravis Foundation of America; 2009. [cited 2020 May 20]. Available from: https://myasthenia.org/Portals/0/Provider%20Manual_ibook%20version.pdf.
   Google Scholar
• Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70:327–334.
   PubMed Web of Science ®Google Scholar
• Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769–772.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;52:1487–1489.
   PubMed Web of Science ®Google Scholar
• Katzberg HD, Barnett C, Merkies IS, et al. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve. 2014;49:661–665.
   PubMed Web of Science ®Google Scholar
• Muppidi S, Wolfe GI, Conaway M, et al. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44:727–731.
   PubMed Web of Science ®Google Scholar
• Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54:1015–1022.
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway M, Sanders DB, et al. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74:1434–1440.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Nowak RJ, Wolfe GI, et al. Zilucoplan, a subcutaneously self-administered peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled trial and open-label long-term extension [data blitz presentation 008]. Neurology. 2019;93:e530.
   Web of Science ®Google Scholar
• US Food and Drug Administration. Search orphan drug designations and approvals: zilucoplan. [cited 2020 May 20]. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=699319
   Google Scholar
• Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology. 2021;96:e610–e618.
   PubMedGoogle Scholar
• Howard JF Jr, Karam C, Yountz M, et al. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Muscle Nerve. 2019;60:135.
   Web of Science ®Google Scholar
• Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14–24.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Pittock SJ, Berthele A, et al. Long-term safety and efficacy of eculizumab in neuromyelitis optica spectrum disorder (1494). Neurology. 2020;94:1494.
   Web of Science ®Google Scholar